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Introduction {#sec001}
============

*Shigella* spp. are recognized as important causative agents of diarrheal diseases in humans \[[@pone.0195259.ref001]--[@pone.0195259.ref004]\]. *Shigella* infections are considered the major public health burden worldwide, especially in the undeveloped and developing countries, and regions with poor sanitary conditions, with an estimated 167 million cases and about 1 million deaths annually; \[[@pone.0195259.ref005]\], and children under five are the most affected group \[[@pone.0195259.ref006]\]. Despite the improvements in economic and health conditions, shigellosis remains one of the top four notifiable infectious diseases, with half a million cases in China \[[@pone.0195259.ref007]--[@pone.0195259.ref009]\].

*Shigella* genus comprises four species, including *Shigella flexneri*, *Shigella dysenteriae*, *Shigella boydii*, and *Shigella sonnei* \[[@pone.0195259.ref010]\], and the distribution of these species and their serotypes shows distinct regional variations. *S*. *flexneri* has primarily been the epidemic species, caused diarrhea in developing countries, while *S*. *sonnei* has been prevalent in the developed countries \[[@pone.0195259.ref011]\]. However, *S*. *sonnei* prevalence has demonstrated an increasing trend in some Asian countries recently \[[@pone.0195259.ref012]--[@pone.0195259.ref015]\], together with the economic development. Furthermore, several serologically atypical isolates of *S*. *flexneri* were identified in recent studies \[[@pone.0195259.ref016]--[@pone.0195259.ref018]\], and these *Shigella* subgroup and serotype variations may lead to difficulties in the prevention and treatment of *Shigella* infection. The emergence and dissemination of antimicrobial resistance (AMR) aggravate *Shigella* prevalence. A trimethoprim/sulfamethoxazole-resistant *Shigella* isolate was first reported in Japan \[[@pone.0195259.ref019],[@pone.0195259.ref020]\], followed by the emergence of diverse resistant *Shigella* types \[[@pone.0195259.ref021],[@pone.0195259.ref022]\]. Previous studies reported a frequent resistance to some of the commonly used antibiotics, such as ampicillin and tetracyclines, worldwide \[[@pone.0195259.ref023]--[@pone.0195259.ref025]\]. Recently, the resistance to quinolones and cephalosporins was reported as well \[[@pone.0195259.ref012],[@pone.0195259.ref026]\]. China is currently facing an increased risk of AMR dissemination among different types of intestinal pathogens. The antibiotic-resistant *Shigella* isolates have been identified throughout China \[[@pone.0195259.ref001],[@pone.0195259.ref007],[@pone.0195259.ref016],[@pone.0195259.ref026]\], aggravating the challenges associated with the treatment and prevention of shigellosis.

As a region located in northwestern China, Xinjiang is bordered by eight countries. Historically, an important trading route, the ancient Silk Road, passed through Xinjiang, leading to the trans-regional migration of different populations. Today, increased contacts between China and other Asian or European countries, due to the proposed development of the Belt and Road, will occur through Xinjiang once more (<http://hkmb.hktdc.com/en/1X0A5D5S/hktdc-research/Xinjiang-A-Core-Component-of-Belt-and-Road>). The increase in the human economic activity may allow faster dissemination of infectious diarrhea pathogens and AMR. Additionally, a comprehensive survey of locally-present infectious pathogens is important to maintain the biosecurity of fast-growing economies. However, the prevalence and characterization of *Shigella* in Xinjiang has not been thoroughly analyzed before \[[@pone.0195259.ref027],[@pone.0195259.ref028]\]. To improve the prevention and treatment of potential future *Shigella* epidemics, we performed detailed analyses of the prevalence and AMR patterns of *Shigella* isolates in Xinjiang, China. We analyzed the variations in *Shigella* species and serotype trends, characterized the AMR profile of these strains, and identified dominant antibiotic-resistant determinants of these isolates.

Material and methods {#sec002}
====================

Bacterial isolation and *Shigella* serotyping {#sec003}
---------------------------------------------

During routine surveillance of bacillary dysentery, fecal samples were collected from patients with diarrhea between 2008 and 2014 in Xinjiang. To isolate *Shigella* strains, the samples were directly streaked on *Salmonella-Shigella* agar (*SS* agar) (Beijing Land Bridge Technology CO., LTD, China) and incubated at 37°C for 16--22 h. The resultant *Shigella*-like colonies were steaked on the *SS* agar again and continually incubated at 37°C for 16--22 h. Following the second incubation, *Shigella* colonies were picked and streaked on Luria-Bertani agar plates, followed by incubation at 37°C for 16--22 h, after which these isolates were identified with API 20E test strips (bioMérieux SA, Marcy l'Etoile, France), according to the manufacturer's instructions. The serotyping of *Shigella* isolates was performed using Shigella Antisera (Denka Seiken, Tokyo, Japan) and monoclonal antibody reagents (MASF IV-1 and MASF IV-2, Reagensia AB, Stockholm, Sweden). Written informed consents were obtained from patients or their guardians. All experiments were approved and authorized by the Ethics Committees of the Institute of Disease Prevention and Control, People's Liberation Army, China.

Antimicrobial susceptibility testing {#sec004}
------------------------------------

Antimicrobial susceptibility testing was performed using the automated broth microdilution (Sensititre; Thermo Fisher Scientific, USA). Minimum inhibitory concentrations (MICs) of 21 antimicrobial agents were determined, including those of piperacillin, ampicillin, ticarcillin, ticarcillin/clavulanic acid, ceftazidime, ceftriaxone, cefepime, cefoperazone, cefazolin, cefoxitin, imipenem, nitrofurantoin, levofloxacin, norfloxacin, tetracycline, tobramycin, gentamicin, amikacin, aztreonam, chloramphenicol, and trimethoprim/sulfamethoxazole. Each isolate was identified as resistant or susceptible to each antibiotic, according to the cut-offs defined by the Clinical and Laboratory Standards Institute (CLSI 2017) \[[@pone.0195259.ref029]\]. *Escherichia coli* ATCC 25922 strain was used as the susceptible control strain.

Detection of AMR determinants and integrons {#sec005}
-------------------------------------------

Total DNA was extracted from all *Shigella* isolate using the TIANamp Bacterial DNA kit (Tiangen Biotech, Beijing, China). β-lactamase genes (*bla*~CTX-M~, *bla*~TEM~, *bla*~OXA~, *bla*~VIM~ and *bla*~NDM~) \[[@pone.0195259.ref030]--[@pone.0195259.ref032]\], quinolone resistance-determining regions (QRDRs) (*gyrA*, *gyrB*, *parC*, and *parE*) \[[@pone.0195259.ref032]\], plasmid-mediated quinolone resistance (PMQR) genes (*qnrA*, *qnrB*, *qnrD*, *qnrS*, and *aac(6')-Ib-cr*) \[[@pone.0195259.ref031]--[@pone.0195259.ref033]\], and the variable regions of class 1 and class 2 integrons \[[@pone.0195259.ref034],[@pone.0195259.ref035]\] were screened using PCR and the primers listed in [S1 Table](#pone.0195259.s002){ref-type="supplementary-material"}. The resulting PCR products were sequenced by BGI, Beijing, China, and the obtained data were edited using DNAstar (DNAstar Inc., Madison, WI, USA) and analyzed using Basic Local Alignment Search Tool in NCBI.

Statistical analysis {#sec006}
--------------------

Differences in the AMR rates and the frequency of AMR determinants between *Shigella* species were analyzed using χ^2^ test. Variations in *Shigella* prevalence with time were analyzed using linear regression. All statistical analyses were performed using Graph Pad 7.0 software, and P \< 0.05 was considered statistically significant.

Results {#sec007}
=======

Identification of isolates and distribution of *Shigella* spp {#sec008}
-------------------------------------------------------------

All *Shigella* isolates in our study were collected from sentinel hospitals in 12 cities or prefectures (Urumqi, Karamay, Kashgar Prefecture, Aksu Prefecture, Hotan Prefecture, Turpan Prefecture, Hami Prefecture, Tacheng Prefecture, Altay Prefecture, Bortala Mongol Autonomous Prefecture, Changji hui autonomous prefecture, Bayingolin Mongol Autonomous Prefecture, Ili Kazakh Autonomous Prefecture). Among all cases, male patient accounted for 55.0%, female accounted for 45.0%; children or teenagers under 18 accounted for 32.9%, adult accounted for 67.1%. In total, we collected 458 *Shigella* isolates between 2008 and 2014 ([Table 1](#pone.0195259.t001){ref-type="table"}). Of these, 365 (79.7%) were identified as *S*. *flexneri* isolates, and 93 (20.3%) were identified as *S*. *sonnei* isolates. *S*. *boydii* and *S*. *dysenteriae* presence was not detected. All collected *S*. *flexneri* isolates belonged to one of at least 16 serotypes ([Fig 1](#pone.0195259.g001){ref-type="fig"}), while serotype 2a (134, 36.7%) was identified as the major *S*. *flexneri* serotype detected during 7 years of surveillance, followed by 1b (47, 12.9%), 2b (46, 12.6%), and Xv (36, 9.9%) ([Fig 1](#pone.0195259.g001){ref-type="fig"}). Some atypical serotypes were identified, including three 1c isolates, four 2c isolates, and seven 4s isolates. Consistently, *S*. *flexneri* was shown to be the dominant *Shigella* species every year, while *S*. *sonnei* isolates accounted for less than 30% of samples ([Fig 2](#pone.0195259.g002){ref-type="fig"}). However, we observed a change in this trend, with the percentage of *S*. *sonnei* among the isolates showing the tendency to increase with time (linear regression analysis, P \< 0.05) ([S1 Fig](#pone.0195259.s001){ref-type="supplementary-material"}). *S*. *sonnei* species, together with the dominant *S*. *flexneri* serotypes (2a, 1b, 2b, and Xv), were shown to constitute the majority of *Shigella* isolates in Xinjiang, with the frequency of above 70% each year ([Table 1](#pone.0195259.t001){ref-type="table"}).

![*S*. *flexneri* serotype distribution.\
Our analyses showed that 2a serotype was the most frequent among 19 identified serotypes. Serotype 2a, 2b, 1b, Xv represent the dominant serotypes, while others were rarely detected.](pone.0195259.g001){#pone.0195259.g001}

![Trends in *Shigella* prevalence in isolates collected in Xinjiang between 2008 and 2014.\
Variations in the frequencies of *S*. *flexneri* and *S*. *sonnei* with time are presented. In each column, frequencies of *S*. *flexneri* and *S*. *sonnei* are shown.](pone.0195259.g002){#pone.0195259.g002}

10.1371/journal.pone.0195259.t001

###### The prevalence of *Shigella* in Xinjiang between 2008 and 2014.

![](pone.0195259.t001){#pone.0195259.t001g}

  Species/ serotype                                  Number (%) of isolates                                                                                  
  -------------------------------------------------- ------------------------ ------------ ------------ ------------ ------------ ------------- ------------ -------------
  ***S*. *flexneri***                                14 (93.3%)               43 (93.5%)   28 (93.3%)   34 (82.9%)   75 (82.4%)   109 (72.7%)   62 (72.9%)   365 (79.7%)
  1a                                                 0                        0            2 (6.7%)     1 (2.4%)     3 (3.3%)     5 (3.3%)      1 (1.2%)     12 (2.6%)
  1b                                                 3 (2)                    3 (6.5%)     7 (23.3%)    7 (17.1%)    6 (6.6%)     13 (8.7%)     8 (9.4%)     47 (10.3%)
  1c                                                 0                        1 (2.2%)     2 (6.7%)     0            0            0             0            3 (0.7%)
  2a                                                 5 (33.3%)                26 (56.5%)   6 (20%)      15 (36.6%)   22 (24.2%)   37 (24.7%)    23 (27.1%)   134 (29.3%)
  2b                                                 2 (13.3%)                4 (8.7%)     5 (16.7%)    7 (17.1%)    8 (8.8%)     15 (10%)      5 (5.9%)     46 (10.0%)
  2c                                                 0                        0            0            1 (2.4%)     1 (1.1%)     2 (1.3%)      0            4 (0.9%)
  3a                                                 1 (6.7%)                 1 (2.2%)     0            2 (4.9%)     0            0             1 (1.2%)     5 (1.1%)
  3b                                                 0                        0            0            0            1 (1.1%)     1 (0.7%)      1 (1.2%)     3 (0.7%)
  4a                                                 0                        0            0            0            1 (1.1%)     2 (1.3%)      2 (2.4%)     5 (1.1%)
  4b                                                 0                        0            0            0            0            2 (1.3%)      0            2 (0.4%)
  Xv                                                 2 (13.3%)                0            2 (6.7%)     1 (2.4%)     13 (14.3%)   9 (6.0%)      9 (10.6%)    36 (7.9%)
  4s                                                 0                        0            0            0            0            7 (4.7%)      0            7 (1.5%)
  6                                                  0                        1 (2.2%)     1 (3.3%)     0            3 (3.3%)     7 (4.7%)      5 (5.9%)     17 (3.7%)
  x                                                  1 (6.7%)                 1 (2.2%)     1 (3.3%)     0            4 (4.4%)     6 (4.0%)      2 (2.4%)     15 (3.3%)
  y                                                  0                        1 (2.2%)     0            0            5 (5.5%)     1 (0.7%)      1 (1.2%)     8 (1.7%)
  Untypable                                          0                        5 (10.9%)    2 (6.7%)     0            8 (8.8%)     2 (1.3%)      4 (4.7%)     21 (4.6%)
  *S*. *flexneri* 2a, 1b, 2b and Xv                  12 (80.0%)               33 (71.7%)   20 (66.7%)   30 (73.2%)   49 (53.8%)   74 (49.3%)    45 (52.9%)   263 (57.4%)
  ***S*. *sonnei***                                  1 (6.7%)                 3 (6.5%)     2 (6.7%)     7 (17.1%)    16 (17.6%)   41 (27.3%)    23 (27.1%)   93 (20.3%)
  *S*. *sonnei*+ *S*. *flexneri* 2a, 1b, 2b and Xv   13 (86.7%)               36 (78.3%)   22 (73.3%)   37 (90.2%)   65 (71.4%)   115 (76.7%)   68 (80.0%)   356 (77.7%)

*Shigella* AMR in Xinjiang {#sec009}
--------------------------

Antimicrobial susceptibility testing demonstrated that *S*. *flexneri* isolates are frequently resistant to ampicillin (94.0%), followed by the resistance to ticarcillin (92.9%), tetracycline (88.8%), chloramphenicol (87.7%), and trimethoprim/sulfamethoxazole (44.4%) ([Table 2](#pone.0195259.t002){ref-type="table"}). Additionally, *S*. *flexneri* isolates showed a significantly higher resistance to several antimicrobials, including ceftazidime, levofloxacin, norfloxacin, ampicillin, ticarcillin, chloramphenicol, and ticarcillin/clavulanic acid, compared with that observed for the *S*. *sonnei* strains (χ^2^ analysis, P \< 0.05). Furthermore, 57 (15.6%) *S*. *flexneri* isolates were shown to be resistant to cephalosporins, including cefazolin (15.3%), ceftriaxone (14.5%), cefoperazone (12.3%), ceftazidime (2.2%), and cefoxitin (0.5%). Moreover, 86 (23.6%) quinolone-resistant *S*. *flexneri* isolates (norfloxacin, 23.6%; levofloxacin, 8.5%) were detected in Xinjiang.

10.1371/journal.pone.0195259.t002

###### Antimicrobial resistance of *Shigella* isolates recovered from patients with diarrhea in Xinjiang, China between 2008 and 2014.
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  --------------------------------------------------------------------------------------------------------------------------------------------
  Antimicrobial agents                              Total\      *S*. *flexneri*\   *S*. *sonnei*\   χ2     P                     
                                                    (n = 458)   (n = 365)          (n = 93)                                      
  ------------------------------------------------- ----------- ------------------ ---------------- ------ ---- ------ --------- -------------
  **Cephems**                                                                                                                    

  FEP                                               0           0                  0                0      0    0      /         /

  FOX                                               2           0.4                2                0.5    0    0      0.5118    P = 0.4744

  CAZ                                               8           1.7                8                2.2    0    0      8.601,    P = 0.0034

  CFP                                               63          13.8               45               12.3   18   19.4   3.084     P = 0.0791

  CRO                                               53          11.6               53               14.5   18   19.4   1.322     P = 0.2502

  CFZ                                               74          16.2               56               15.3   18   19.4   0.8808    P = 0.3480

  **Fluoroquinolones**                                                                                                           

  LEV                                               31          6.8                31               8.5    0    0      8.472     P = 0.0036

  NOR                                               86          18.8               86               23.6   0    0      26.98     P \< 0.0001

  **Carbapenems**                                                                                                                

  IMP                                               0           0.0                0                0      0    0      /         /

  **Penicillins**                                                                                                                

  PIP                                               66          14.4               45               12.3   21   22.6   6.316     P = 0.0120

  TIC                                               399         87.1               339              92.9   60   64.5   53.12     P \< 0.0001

  AMP                                               403         88.0               343              94     60   64.5   60.86     P \< 0.0001

  **Aminoglycosides**                                                                                                            

  AK                                                1           0.2                1                0.3    0    0      0.2554    P = 0.6133

  TO                                                11          2.4                9                2.5    2    2.1    0.03142   P = 0.8593

  GN                                                57          12.4               16               4.4    41   44.1   107.2     P \< 0.0001

  **Monobactams**                                                                                                                

  ATM                                               33          7.2                18               4.9    15   16.1   13.9      P = 0.0002

  **Nitrofurans**                                                                                                                

  NIT                                               0           0.0                0                0      0    0      /         /

  **Tetracyclines**                                                                                                              

  TE                                                407         88.9               324              88.8   83   89.2   0.01727   P = 0.8954

  **Phenicols**                                                                                                                  

  C                                                 322         70.3               320              87.7   2    2.1    259.7     P \< 0.0001

  **β-Lactam/β-lactamase inhibitor combinations**                                                                                

  TIM                                               35          7.6                34               9.3    1    1.1    7.13      P = 0.0076

  **Folate pathway inhibitors**                                                                                                  

  SXT                                               249         54.4               162              44.4   87   93.5   72.21     P \< 0.0001
  --------------------------------------------------------------------------------------------------------------------------------------------

AK, amikacin; AMP, ampicillin; ATM, aztreonam; CFZ, cefazolin; FEP, cefepime; CFP, cefoperazone; FOX, cefoxitin; CAZ, ceftazidime; CRO, ceftriaxone; C, chloramphenicol; GEN, gentamicin; IPM, imipenem; LEV, levofloxacin; NIT, nitrofurantoin; NOR, norfloxacin; PIP, piperacillin; SXT, trimethoprim/sulfamethoxazole; TE, tetracycline; TIC, ticarcillin; TIM, ticarcillin/clavulanic acid; TO, tobramycin.

In contrast, *S*. *sonnei* species was shown to be the most resistant to trimethoprim/sulfamethoxazole (93.5%), followed by the resistance to tetracycline (89.2%), ticarcillin (64.5%), ampicillin (64.5%), gentamicin (44.1%) ([Table 2](#pone.0195259.t002){ref-type="table"}). Furthermore, *S*. *sonnei* showed a significantly higher resistance rates to some antibiotics, including piperacillin, gentamicin, aztreonam, and trimethoprim/sulfamethoxazole, compared with those obtained for *S*. *flexneri* isolates (χ^2^, P \< 0.05). Additionally, *S*. *sonnei* isolates showed resistance to cephalosporins, including cefazolin (19.4%), ceftriaxone (19.4%), and cefoperazone (19.4%). None of these isolates was resistant to other cephalosporins, such as cefepime, cefoxitin, and ceftazidime, and to quinolones (levofloxacin and norfloxacin; [Table 2](#pone.0195259.t002){ref-type="table"}).

Furthermore, 330 (90.4%) of 365 *S*. *flexneri* isolates and 59 (63.4%) of 93 *S*. *sonnei* isolates were shown to be multidrug resistant (MDR, resistant to three or more CLSI classes of antimicrobials) ([Table 3](#pone.0195259.t003){ref-type="table"} and [S2 Table](#pone.0195259.s003){ref-type="supplementary-material"}). *S*. *flexneri* species showed a significantly higher frequency of MDR than *S*. *sonnei* species (χ^2^, P \< 0.05). *S*. *flexneri* exhibited MDR to at most 7 classes of antimicrobial and *S*. *sonnei* showed MDR to at most 5 classes of antimicrobials. Besides, there were some *S*. *flexneri* isolates with important MDR phenotypes, including 136 (37.3%) *S*. *flexneri* isolates resistant to at least ampicillin, chloramphenicol, tetracycline and trimethoprim/sulfamethoxazole; 38 (10.4%) *S*. *flexneri* isolates resistant to at least ampicillin, chloramphenicol, tetracycline, trimethoprim/sulfamethoxazole and norfloxacin; 22 (6%) *S*. *flexneri* isolates resistant to at least ampicillin, chloramphenicol, tetracycline, trimethoprim/sulfamethoxazole and ceftriaxone; 9 (2.5%) *S*. *flexneri* isolates resistant to at least ampicillin, chloramphenicol, tetracycline, trimethoprim/sulfamethoxazole, norfloxacin and ceftriaxone. Notably, these important MDR phenotypes have not been observed in *S*. *sonnei* isolates.

10.1371/journal.pone.0195259.t003

###### Antimicrobial resistance profiles of *Shigella* isolates in Xinjiang between 2008 and 2014.
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  Antibiotic[\*](#t003fn001){ref-type="table-fn"}   Number of isolates (%)   
  ------------------------------------------------- ------------------------ -----------
  No resistance detected                            12 (3.3)                 3 (3.2)
  Resistant ≥ 1 CLSI class                          353 (96.7)               90 (96.8)
  Resistant ≥ 2 CLSI classes                        349 (95.6)               90 (96.8)
  Resistant ≥ 3 CLSI classes                        330 (90.4)               59 (63.4)
  Resistant ≥ 4 CLSI classes                        200 (54.8)               53 (57.0)
  Resistant ≥ 5 CLSI classes                        62 (17.0)                14 (15.1)
  Resistant ≥ 6 CLSI classes                        21 (5.8)                 0
  Resistant = 7 CLSI classes                        8 (2.2)                  0
  Cephalosporin                                     57 (15.6)                18 (19.4)
  Quinolones                                        86 (23.6)                0
  Cephalosporin and quinolones                      17 (4.7)                 0
  At least ACTT/S                                   136 (37.3)               0
  At least ACTT/SNOR                                38 (10.4)                0
  At least ACTT/SCRO                                22 (6.0)                 0
  At least ACTT/SCRONOR                             9 (2.5)                  0

\*A, ampicillin; C, chloramphenicol; CRO, ceftriaxone; NOR, norfloxacin; T, tetracycline; T/S, trimethoprim/sulfamethoxazole.

Detection of AMR determinants and integrons {#sec010}
-------------------------------------------

A total of 57 (15.6%) *S*. *flexneri* and 18 (19.4%) *S*. *sonnei* isolates showing high-level resistance to cephalosporin were selected to detect the presence of antibiotic-resistance determinant genes and integrons ([Table 4](#pone.0195259.t004){ref-type="table"}). Rates of *bla*~OXA-1~, *bla*~TEM-1,~ and *bla*~CTX-M~ expression among the selected *S*. *flexneri* isolates were 82.5%, 61.4%, and 89.5%, respectively. Moreover, 48 *S*. *flexneri* isolates contained the CTX-M gene, including 23 (40.4%) isolates containing CTX-M-1 group genes, 29 (50.9%) isolates with CTX-M-9 group genes, and 4 (7.0%) isolates containing both group genes. No expression of *bla*~VIM~ and *bla*~NDM~ was observed in the tested isolates. Furthermore, the majority of tested *S*. *flexneri* isolates was shown to harbor integrons, including 49 (86.0%) isolates that were shown to harbor class 1 integrons and 51 (89.4%) that harbored class 2 integrons ([Table 4](#pone.0195259.t004){ref-type="table"}). In contrast to the *S*. *flexneri* isolates, all selected *S*. *sonnei* isolates were negative for *bla*~OXA-1~ expression, while only 38.9% expressed *bla*~TEM~ ([Table 4](#pone.0195259.t004){ref-type="table"}). The expression rate of class 1 integrons detected in *S*. *sonnei* isolates (5.6%) was considerably lower than that in the *S*. *flexneri* isolates (86.0%), while the rate of isolates expressing class 2 integrons reached 83.3%. All 18 tested cephalosporin-resistant *S*. *sonnei* isolates were demonstrated to harbor *bla*~CTX-M~ genes, including 14 (77.8%) isolates with CTX-M-1 group genes, nine (50%) isolates containing CTX-M-9 group genes, and six (33.3%) isolates carrying genes from both of these groups ([Table 4](#pone.0195259.t004){ref-type="table"}). Among cephalosporin-resistant isolates, a higher frequency of isolates carrying both CTX-M-1 and CTX-M-9 group genes was detected among *S*. *sonnei* isolates, compared with that observed among *S*. *flexneri* isolates (χ^2^ analysis, P \< 0.05).

10.1371/journal.pone.0195259.t004

###### Antimicrobial resistance determinants in 75 cephalosporin-resistant *Shigella* isolates and 86 quinolone-resistant *Shigella* isolates.
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  Resistant determinant                          Number of isolates (%)                                      
  ---------------------------------------------- ------------------------------ ---------------------------- --------------------
  **Determinants of cephalosporin resistance**   ***S*. *flexneri* (n = 57)**   ***S*. *sonnei* (n = 18)**   **Total (n = 75)**
  *bla*~VIM~                                     0                              0                            0
  *bla*~NDM~                                     0                              0                            0
  *bla*~OXA~                                     47 (82.5)                      0                            47 (62.7)
  *bla*~TEM~                                     35 (61.4)                      7 (38.9)                     42 (56.0)
  *bla*~CTX-M~                                   51 (89.5)                      18 (100%)                    69 (92.0)
  CTX-M-1 group                                  23 (40.4)                      14 (77.8)                    37 (49.3)
  *bla*~CTX-M-3~                                 3 (5.3)                        0 (0)                        3 (4.0)
  *bla*~CTX-M-15~                                10 (17.5)                      7 (38.9)                     17 (22.7)
  *bla*~CTX-M-28~                                2 (3.5)                        0 (0)                        2 (2.7)
  *bla*~CTX-M-55~                                6 (10.5)                       7 (38.9)                     13 (17.3)
  *bla*~CTX-M-64~                                2 (3.5)                        0 (0)                        2 (2.7)
  CTX-M-9 group                                  29 (50.9)                      4 (22.2)                     33 (44.0)
  *bla*~CTX-M-14~                                26 (45.6)                      4 (22.2)                     30 (40.0)
  *bla*~CTX-M-24~                                3 (5.3)                        0 (0)                        3 (4.0)
  Both CTX-M-1 and CTX-M-9 group                 4 (7.0)                        6 (33.3)                     10 (13.3)
  *intl1*                                        49 (86.0)                      1 (5.6)                      50 (66.7)
  *intl2*                                        51 (89.5)                      15 (83.3)                    66 (88.0)
  *hep74-51*                                     49 (86.0)                      17 (94.4)                    66 (88.0)
  **Determinants of resistance to quinolones**   ***S*. *flexneri* (n = 86)**   ***S*. *sonnei* (n = 0)**    **Total (n = 86)**
  QRDRs mutations                                86 (100)                       0                            86 (100)
  *gyrA*                                         86 (100)                       0                            86 (100)
  *Ser83Leu*                                     86 (100)                       0                            86 (100)
  *Asp87Asn*                                     62 (72.1)                      0                            62 (72.1)
  *Asp87Gly*                                     16 (18.6)                      0                            16 (18.6)
  *His211Tyr*                                    82 (95.3)                      0                            82 (95.3)
  *gyrB*                                         0                              0                            0
  *parE*                                         0                              0                            0
  *parC*                                         86 (100)                       0                            86 (100)
  *Ser80Ile*                                     86 (100)                       0                            86 (100)
  Triple (or more) mutations                     86 (100)                       0                            86 (100)
  Four mutations                                 74 (86.0)                      0                            74 (86.0)
  PMQR genes                                     3 (3.5)                        0                            3 (3.5)
  *qnrB*                                         1 (1.2)                        0                            1 (1.2)
  *qnrS*                                         2 (2.3)                        0                            2 (2.3)
  *acc (6')-Ib-cr*                               0                              0                            0

Moreover, in this study, we identified 86 *S*. *flexneri* isolates resistant to quinolones (levofloxacin or norfloxacin) ([Table 4](#pone.0195259.t004){ref-type="table"}). QRDR mutations were detected in three amino acids of the *gyrA* gene (Ser83Leu, Asp87Asn/Gly, His211Tyr) and one amino acid of the *parC* gene (Ser80Ile). All 86 isolates were shown to harbor Ser83Leu mutations in the *gyrA* and Ser80Ile in the *parC* genes. Additionally, 62 isolates were shown to carry Asp87Asn mutation in the *gyrA* gene, 16 isolates had Asp87Gly mutation in the *gyrA* and 82 isolates had His211Tyr mutation in the *gyrA* gene. No point mutations in the *gyrB* and *parE* genes were observed. All 86 quinolone-resistant isolates were identified to carry at least three types of QRDR mutations, and 74 (86.0%) isolates were shown to harbor four types of QRDR mutations. In contrast, only three isolates were shown to harbor PMQR gene mutations (one in *qnrB*, two in *qnrS*), and no isolates were positive for *acc(6′)-Ib-cr*.

Notably, 17 *Shigella* isolates were resistant to cephalosporins and quinolones simultaneously ([Table 5](#pone.0195259.t005){ref-type="table"}), and these were the MDR *S*. *flexneri* strains. Other than the resistance to cephalosporins and quinolones, the resistance to penicillins (17, 100%) was one of the most frequent types of resistance, followed by the resistance to tetracyclines (16, 94.1%), amphenicols (15, 88.2%), folate pathway inhibitors (13, 76.5%), and monobactams (6, 35.3%). Molecular analysis of the resistance determinants in 17 isolates, demonstrated the expression of *bla*~OXA-1~ in 16 isolates, *bla*~TEM-1~ in 14 isolates, and *bla*~CTX-M~ in 15 isolates. Quinolone resistance of all 17 isolates was shown to be mediated by the mutations in QRDRs of *gyrA* and *parC*, since no isolate was shown to have PMQR gene mutations. Integrons and gene cassette arrays were identified in a number of isolates, including 17 isolates shown to carry integrons, 16 isolates with class 1 integrons, and 16 with class 2 integrons.

10.1371/journal.pone.0195259.t005

###### Antimicrobial resistance profiles and resistance determinants of 17 *Shigella* isolates co-resistant to cephalosporin and quinolone.

![](pone.0195259.t005){#pone.0195259.t005g}

  Isolate   Antimicrobial resistance profile                       β-Lactamases gene   QRDRs mutation   PMQR gene              Integron                                  
  --------- ------------------------------------------------------ ------------------- ---------------- ---------------------- ------------------- ------ ---- ---- ---- ----
  XJSF20    CRO/CFZ/TIC/AMP/NOR/TE/C/STX                           \+                  \+               *bla*~CTX-M-15~        S83L, D87N, H211Y   S80I   \-   \+   \+   \+
  XJSF22    CRO/CFP/CFZ/TIC/AMP/PIP/NOR/TE/ATM/C/STX               \+                  \+               *bla*~CTX-M-55~        S83L, D87G, H211Y   S80I   \-   \+   \+   \+
  2010048   CRO/CFP/CFZ/TIC/AMP/PIP/NOR/TE/ATM/C/STX               \+                  \+               *bla*~CTX-M-55~        S83L, D87N, H211Y   S80I   \-   \+   \+   \+
  2011109   CRO/CFP/CFZ/TIC/TIM/AMP/PIP/NOR/GN/TE/ATM/C/STX        \+                  \+               *bla*~CTX-M-55~        S83L, D87G, H211Y   S80I   \-   \+   \+   \+
  2012064   CAZ/CRO/CFP/CFZ/TIC/AMP/NOR/TE/C                       \+                  \+               *bla*~CTX-M-15~        S83L, D87G, H211Y   S80I   \-   \+   \+   \+
  2012076   CRO/CFP/CFZ/TIC/TIM/AMP/PIP/LEV/NOR/TE/ATM/C/STX       \+                  \+               *bla*~CTX-M-15~        S83L, H211Y         S80I   \-   \+   \+   \+
  2012085   CFZ/TIC/TIM/AMP/NOR/TE/C/STX                           \+                  \+               \-                     S83L, D87N, H211Y   S80I   \-   \+   \+   \+
  2012131   CRO/CFP/CFZ/TIC/AMP/PIP/NOR/TE/ATM/C                   \+                  \+               *bla*~CTX-M-55~        S83L, D87G, H211Y   S80I   \-   \+   \+   \+
  2012136   CRO/CFP/CFZ/TIC/TIM/AMP/PIP/LEV/NOR/C                  \+                  \+               *bla*~CTX-M-14~        S83L, D87N, H211Y   S80I   \-   \+   \+   \+
  2012262   CRO/CFP/CFZ/TIC/TIM/AMP/PIP/NOR/TE/C                   \+                  \+               \-                     S83L, D87G, H211Y   S80I   \-   \+   \+   \+
  2013269   CAZ/CRO/CFP/CFZ/TIC/TIM/AMP/PIP/LEV/NOR/TE/ATM/C/STX   \+                  \+               *bla*~CTX-M-15~        S83L, D87N, H211Y   S80I   \-   \+   \+   \+
  2013398   CRO/CFP/CFZ/TIC/TIM/AMP/PIP/LEV/NOR/GN/TE/C/STX        \+                  \+               *bla*~CTX-M-14~        S83L, H211Y         S80I   \-   \+   \+   \+
  2013416   CRO/CFP/CFZ/TIC/AMP/PIP/NOR/TE/ATM/C/STX               \+                  \+               *bla*~CTX-M-14,\ 64~   S83L, D87N, H211Y   S80I   \-   \+   \+   \+
  2014104   CRO/CFP/CFZ/TIC/AMP/PIP/LEV/NOR/GN/TE/ATM/STX          \-                  \-               *bla*~CTX-M-15~        S83L, D87N, H211Y   S80I   \-   \+   \-   \-
  2014331   CRO/CFP/CFZ/TIC/AMP/PIP/NOR/TE/ATM/C/STX               \+                  \+               *bla*~CTX-M-15~        S83L, D87N, H211Y   S80I   \-   \+   \+   \+
  2014351   CRO/CFZ/TIC/AMP/LEV/NOR/TE/C/STX                       \+                  \-               *bla*~CTX-M-14~        S83L, H211Y         S80I   \-   \-   \+   \+
  2014366   CRO/CFZ/TIC/AMP/LEV/NOR/TE/C/STX                       \+                  \-               *bla*~CTX-M-15~        S83L, D87N, H211Y   S80I   \-   \+   \+   \+

AK, amikacin; AMP, ampicillin; ATM, aztreonam; CFZ, cefazolin; FEP, cefepime; CFP, cefoperazone; FOX, cefoxitin; CAZ, ceftazidime; CRO, ceftriaxone; C, chloramphenicol; GEN, gentamicin; IPM, imipenem; LEV, levofloxacin; NIT, nitrofurantoin; NOR, norfloxacin; PIP, piperacillin; SXT, trimethoprim/sulfamethoxazole; TE, tetracycline; TIC, ticarcillin; TIM, ticarcillin/clavulanic acid; TO, tobramycin.

Discussion {#sec011}
==========

Here, we demonstrated that the most frequent species of *Shigella* genus in Xinjiang in all years of our study was *S*. *flexneri*. Recently, the *S*. *sonnei* has shown increasing prevalence in China and even become the dominant species in southeast and central parts of China \[[@pone.0195259.ref036]\]. Furthermore, together with the economic growth in Xinjiang, an obvious rising trend in *S*. *sonnei* infections can be observed. The frequency of identified *S*. *sonnei* isolates altered from 6.7% in 2008 to 27.1% in 2014, which was, even considering the increase, shown to be below the average frequency of *S*. *sonnei* infections registered in China, where it was the dominant *Shigella* species (58.2% in 2011--2013) \[[@pone.0195259.ref036]\]. Various studies have concluded that *S*. *sonnei* prevalence increase with economic development \[[@pone.0195259.ref037]\]. As Xinjiang will continue to enhance its level of economy and sanitation, it is likely that *S*. *sonnei* species would become even more of a local public health concern. The design of vaccine candidate and shigellosis prevention strategy should consider this change of *Shigella* epidemics.

Considering serotypes, 2a and Xv were reported to be dominant *S*. *flexneri* serotypes in China \[[@pone.0195259.ref036]\], and 2a was reported to be dominant *S*. *flexneri* serotype in Xinjiang \[[@pone.0195259.ref027]\]. However, the results of our study further demonstrated that 2a serotype was still the most prevalent in Xinjiang but Xv serotype accounted for a smaller proportion of *S*. *flexneri* isolates, while 2a, 1b, 2b, and Xv represent the dominant serotypes detected between 2008 and 2014. Serotypes 1b and 2b are less frequent in China \[[@pone.0195259.ref036]\], but common in Pakistan \[[@pone.0195259.ref038]\], a country bordering Xinjiang. Therefore, the dominant *S*. *flexneri* serotypes distributed in Xinjiang likely represent the mixture of the major serotypes in China and adjacent countries.

Furthermore, we detected atypical serotypes 1c, 2c, and 4s in Xinjiang. Serotype-based vaccines are currently under development, as a promising strategy against *Shigella* epidemics \[[@pone.0195259.ref039]\]. A future *Shigella* vaccine potentially applied in Xinjiang should be developed in accordance considering the characteristic *Shigella* serotypes in this region, and future surveillance studies in Xinjiang should pay close attention not only to the newly emerged serotypes but the predominant subgroups in surrounding regions as well, in order to prevent potential *Shigella* epidemics caused by bacteria with novel or imported O-antigen types.

*Shigella* isolates demonstrated high levels of resistance to antibiotics. Both *S*. *flexneri* and *S*. *sonnei* revealed high AMR rate to some common used antibiotics like penicillins and tetracyclines. Thus, these older-generation drugs should not be contained in empirical therapy of shigellosis. Notably, 330 of 365 *S*. *flexneri* isolates and 59 of 93 *S*. *sonnei* isolates collected from Xinjiang showed MDR profiles. The high-level MDR frequency further restrict the choice of antibiotics in the clinical treatment of bacterial infections. Since the efficacy of older-generation antibiotics decreased due to the development of resistant strains, in a previous study, quinolones and third-generation cephalosporins were recommended as frontline antimicrobials for the empiric treatment of diarrhea-inducing pathogens \[[@pone.0195259.ref040]\]. However, in our study, 75 (16.38%) isolates were resistant to cephalosporin and 86 (18.77%) were resistant to norfloxacin. Additionally, 17 (3.71%) isolates were resistant to both cephalosporins and quinolones. Considering the currently used frontline antimicrobials, these resistance phenotypes threaten the effectiveness of therapy \[[@pone.0195259.ref041],[@pone.0195259.ref042]\]. The mobility and dissemination of the resistant strains may increase in Xinjiang as it becomes an increasingly crucial region connecting China and other countries. Surveillance to *Shigella* in China revealed its high MDR frequency \[[@pone.0195259.ref007],[@pone.0195259.ref016],[@pone.0195259.ref017],[@pone.0195259.ref026],[@pone.0195259.ref043],[@pone.0195259.ref044]\]. The high-level resistant pathogen could migrate along with increasing trans-regional human activities. Therefore, novel preventive strategies are urgently required to prevent the spreading of AMR among *Shigella* strains. Clinicians prescribing anti-infective therapies should be more cautious, since the unreasonable use of antibiotics may further accelerate the accumulation and spread of AMR \[[@pone.0195259.ref045]--[@pone.0195259.ref047]\].

The AMR profile differed between *S*. *flexneri* and *S*. *sonnei* strains. Specifically, *S*. *flexneri* revealed higher MDR levels, demonstrating also some specific and important MDR phenotypes. A proportion of *S*. *flexneri* strains (37.3%) was shown to be resistant to the combination of commonly used antibiotics, including ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole, which was not observed among *S*. *sonnei* isolates. Quinolone resistance and even co-resistance to cephalosporin and quinolone emerged in *S*. *flexneri* strains, while *S*. *sonnei* demonstrated the sensitivity to quinolone. As a long-term predominant species in China \[[@pone.0195259.ref048]\], the traditional antibiotic-associated selection of *S*. *flexneri* has been underway for decades, and by frontline antibiotics in recent years, which led to the development of the MDR strains and the resistance to cephalosporin and quinolone. Therefore, our results imply that the antibiotic therapy of choice may differ between two *Shigella* species. Treatment of *S*. *flexneri* infections may be more complicated than that of *S*. *sonnei*, and a drug susceptibility test should be performed immediately after diagnosing a patient with *S*. *flexneri* infection. Antibiotic abuse should be more controlled, in order to reduce the selection pressure on *S*. *flexneri* strains, but the quinolone treatment may represent a safer antibiotic choice if the infective pathogens are identified as *S*. *sonnei*.

In this study, we further elucidated the genetic background and mechanisms underlying *Shigella* resistance to cephalosporins and quinolones. Cephalosporin-resistant *S*. *flexneri* were shown to frequently express *bla*~CTX-M~, *bla*~OXA~, and *bla*~TEM~, three main genes conferring the resistance to cephalosporin \[[@pone.0195259.ref049],[@pone.0195259.ref050]\]. All cephalosporin-resistant *S*. *sonnei* expressed *bla*~CTX-M~ as well. These genes were reported to be frequently encoded by plasmids \[[@pone.0195259.ref051]--[@pone.0195259.ref055]\], which facilitates the horizontal transfer of resistance to β-lactamase antibiotics \[[@pone.0195259.ref049],[@pone.0195259.ref056]\]. Previous studies reported that class 1 and class 2 integrons may provide the resistance to other types of drugs and be responsible for the dissemination of AMR \[[@pone.0195259.ref035],[@pone.0195259.ref057],[@pone.0195259.ref058]\]. Almost 90% of the isolated *S*. *flexneri* strains were shown to harbor two integrons. The *intl2* was also frequently identified in the *S*. *sonnei* isolates (83.3%). These results indicate that the cephalosporin resistance determinants can actively disseminate among *Shigella* cells or transferr within microflora. The PMQR genes were reported to be always located in mobile genetic elements such as plasmids \[[@pone.0195259.ref059]\]. Here, the presence of *qnrS* and *qnrB* genes was detected at a very low level in quinolone-resistant *S*. *flexneri* in Xinjiang, while a number of QRDR mutations were identified, indicating that the mutations in QRDRs primarily underlie the resistance to quinolone in *Shigella* isolates investigated here. Different QRDR mutations confer various levels of resistance \[[@pone.0195259.ref060]--[@pone.0195259.ref062]\]. Notably, all quinolone-resistant isolates were shown to harbor at least three QRDR mutations, showing that their simultaneous presence may underlie the observed increase in the resistance to quinolones.

We analyzed and presented here the prevalence of *Shigella* species and serotypes in Xinjiang, China. *S*. *flexneri* was shown to be the dominant *Shigella* species, with a unique dominant serotype pattern (2a, 1b, 2b, Xv), which represents a hybrid pattern comprising serotypes prevalent in adjacent regions. High levels of AMR were observed, especially by *S*. *flexneri* isolates. Emergence of frequently observed MDR and resistance to frontline antibiotics can severely restrict the choice of antibiotic therapy used for the treatment of *Shigella* infections. Since unsafe sanitation conditions remain present in this region, food-borne or water-borne shigellosis epidemic will remain a significant public health concern in future \[[@pone.0195259.ref063],[@pone.0195259.ref064]\]. Therefore, the prevalence, trends, and AMR patterns of *Shigella* species and serotypes in Xinjiang should be closely monitored, and novel strategies are urgently required to prevent the spreading of the AMR among *Shigella* strains.
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###### Variations in *S*. *sonnei* prevalence with time.

An increasing trend in *S*. *sonnei* frequency among the *Shigella* isolates was observed between 2008 and 2014.

(TIF)

###### 

Click here for additional data file.

###### Primers used for the PCR amplification of antibiotic resistance genes.

(DOCX)

###### 

Click here for additional data file.
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